FABP4 and metabolic dysfunction-associated steatotic liver disease: In MASLD, FABP4 overexpression promotes the uptake of FFAs and the synthesis of triglycerides (TGs), leading to hepatic steatosis, while also inhibiting fatty acid β-oxidation, exacerbating lipid accumulation [40].